Health
Adderall Alternative Vyvanse Is in Low Supply as ADHD Drug Shortages Spread
- Manufacturing issues could hit supply through September
- Prescriptions for Vyvnanse have been up since early 2023
This article is for subscribers only.
Supply of a common Adderall alternative is running low, further limiting options for US patients amid a national shortage of ADHD drugs that has lasted almost a year.
Vyvanse, sold by Takeda Pharmaceutical Co., is in low inventory due to manufacturing issues, a company spokesperson told Bloomberg News. “Increased demand for Vyvanse in the wake of other ADHD medication supply shortages has limited our ability to have additional inventory on-hand to help mitigate potential supply disruptions,” a representative wrote in an email.